Patent classifications
C07D521/00
COMPOUNDS THAT INDUCE FERROPTIC CELL DEATH
The diterpene natural product pleuromutilin was subjected to reaction sequences focused on creating ring system diversity in few synthetic steps. This effort resulted in a collection of compounds with previously unreported ring systems, providing a novel set of structurally diverse and highly complex compounds suitable for screening in a variety of different settings. Biological evaluation identified the novel compound ferroptocide, a small molecule that rapidly and robustly induces ferroptotic death of cancer cells. Target identification efforts and CRISPR knockout studies reveal that ferroptocide is an inhibitor of thioredoxin, a key component of the antioxidant system in the cell. Ferroptocide positively modulates the immune system in a murine model of breast cancer and will be a useful tool to study the utility of pro-ferroptotic agents for treatment of cancer.
Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals
The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.
Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals
The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.
PAPD5 INHIBITORS AND METHODS OF USE THEREOF
The disclosure relates to compounds that are, e.g., PAP Associated Domain Containing 5 (PAPD5) inhibitors and methods of use thereof.
KRAS MUTANT PROTEIN INHIBITORS
The invention relates to a KRAS mutant protein inhibitor, a composition containing the inhibitor and the use thereof.
##STR00001##
Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals
The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.
Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals
The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.
Organic compound and light emitting diode and organic light emitting diode display device using the same
The present disclosure relates to an organic compound, a light emitting diode and an organic light emitting diode display device using the same. The organic compound is represented by a following chemical formula 1. ##STR00001## This organic compound has the advantages in the thermal stability, the emission property, the color purity, the hole transport property and the hole movement property, and thus the lifetime, the emission efficiency and the emission property of the LED using the same are improved.
Organic compound and light emitting diode and organic light emitting diode display device using the same
The present disclosure relates to an organic compound, a light emitting diode and an organic light emitting diode display device using the same. The organic compound is represented by a following chemical formula 1. ##STR00001## This organic compound has the advantages in the thermal stability, the emission property, the color purity, the hole transport property and the hole movement property, and thus the lifetime, the emission efficiency and the emission property of the LED using the same are improved.
Compounds and methods for the targeted degradation of bromodomain-containing proteins
The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.